Cinclus Pharma Holding AB (FRA:J8P) Institutional Ownership: 1.69% (As of Aug. 04, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:J8P Cinclus Pharma Holding AB FRA:J8P
6 GF Score
Price €1.04
! 3 Warning Signs
View Full Analysis

What is Cinclus Pharma Holding AB Institutional Ownership?

Cinclus Pharma Holding AB FRA:J8P +0.97% 6 Institutional Ownership is 1.69% as of Aug. 04, 2026. GuruFocus rates FRA:J8P with a GF Score™ of 6/100. The stock has 3 warning signs investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Cinclus Pharma Holding AB's institutional ownership is 1.69%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Cinclus Pharma Holding AB's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Cinclus Pharma Holding AB's Float Percentage Of Total Shares Outstanding is 0.00%.

Cinclus Pharma Holding AB Institutional Ownership Historical Data

* Premium members only.

The historical data trend for Cinclus Pharma Holding AB's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cinclus Pharma Holding AB Institutional Ownership Chart

Cinclus Pharma Holding AB Historical Data

The historical data trend for Cinclus Pharma Holding AB can be seen below:

2025-09-30 2025-10-31 2025-11-30 2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-05-31 2026-06-30
Institutional Ownership 1.55 1.56 1.56 1.55 1.55 1.55 1.55 1.55 1.61 1.69
FRA:J8P
6GF Score
Cinclus Pharma Holding AB FRA:J8P
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cinclus Pharma Holding AB Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 1.69% mean?
Cinclus Pharma Holding AB (FRA:J8P) has a Institutional Ownership of 1.69% as of Aug. 04, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Cinclus Pharma Holding AB and its competitors.
Is Cinclus Pharma Holding AB's Institutional Ownership too high?
Cinclus Pharma Holding AB's current Institutional Ownership is 1.69%. Overall, Cinclus Pharma Holding AB has a GF Score™ of 6/100, reflecting its overall financial health beyond just this single metric.
How does Cinclus Pharma Holding AB's Institutional Ownership compare to ZTS?
Cinclus Pharma Holding AB's Institutional Ownership of 1.69% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Drug Manufacturers company?
A good Institutional Ownership depends on the Drug Manufacturers industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Cinclus Pharma Holding AB and its competitors. Cinclus Pharma Holding AB's current Institutional Ownership is 1.69%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cinclus Pharma Holding AB stock overvalued right now?
Cinclus Pharma Holding AB (FRA:J8P) has a current Institutional Ownership of 1.69%. The current Institutional Ownership is 1.69%. Cinclus Pharma Holding AB's overall GF Score™ is 6/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For Cinclus Pharma Holding AB (FRA:J8P), the current Institutional Ownership is 1.69% as of Aug. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cinclus Pharma Holding AB Business Description

Other Exchanges CINPHA:Sweden
Address Kungsbron 1, Stockholm, SWE, SE-111 22
Cinclus Pharma Holding AB is a Swedish clinical-stage pharmaceutical company focused on developing small-molecule treatments for gastric acid-related diseases. Its candidate, linaprazan glurate, is being developed for the treatment of severe gastroesophageal reflux disease, including erosive forms. The company is also developing a dual therapy treatment with an antibiotic targeting Helicobacter pylori, a bacterium found in the gastric and duodenal mucosa. Its primary target population consists of patients with severe erosive gastroesophageal reflux disease, where current treatment options are limited. It operates in Switzerland, Sweden, and the Czech Republic, with the majority of revenue from the Czech Republic.
6GF Score

Get the complete analysis for FRA:J8P

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.04
Price